K
Khufu Therapeutics develops a Synthetic, Personalized, Rejuvenated (SPR) Platform to permanently restore liver mass and function in cirrhosis patients. This first-in-class technology integrates stem cell biology, organ engineering, and AI-driven computational modeling for in vivo tissue regeneration. The company offers a non-transplant alternative that rebuilds functional liver architecture using the patient's own cells.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Khufu Therapeutics develops a Synthetic, Personalized, Rejuvenated (SPR) Platform to treat cirrhosis by regenerating functional liver tissue inside the body. This first-in-class technology integrates stem cell biology, organ engineering, and AI-driven computational modeling. The approach aims to permanently restore liver mass, architecture, and function without requiring transplantation or immunosuppression.